Effect of polycan, a β‑glucan originating from Aureobasidium, on a high‑fat diet‑induced hyperlipemic hamster model

Lim,Mee‑Kyoung; Ku,Sae-Kwang; Choi,Jae‑Suk; Kim,Joo‑Wan

doi:10.3892/etm.2015.2238

Effect of polycan, a β‑glucan originating from Aureobasidium, on a high‑fat diet‑induced hyperlipemic hamster model

Authors:
- Mee‑Kyoung Lim
- Sae-Kwang Ku
- Jae‑Suk Choi
- Joo‑Wan Kim
View Affiliations

Affiliations: Department of Food Science and Nutrition, School of Human Ecology, Kyungpook National University, Daegu 702‑701, Republic of Korea, Department of Anatomy and Histology, College of Oriental Medicine, Daegu Haany University, Gyeongsan 712-715, Republic of Korea , Department of Bio‑Food Materials, Silla University, Busan 617‑736, Republic of Korea, Glucan Corporation, Marine Bio‑Industry Development Center, Busan 619‑912, Republic of Korea
Published online on: January 29, 2015 https://doi.org/10.3892/etm.2015.2238
Pages: 1369-1378

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to analyze the effect of polycan, a β‑glucan originating from Aureobasidium, on high‑fat diet (HFD)‑induced hyperlipemia and hepatic damage. A total of 30 hamsters were divided into 6 groups based on their body weight following acclimatization: control, sham, simvastatin (SIMVA) and 3 Polycan groups. In the polycan groups, Polycan, at three concentrations (31.25, 62.5 and 125 mg/kg), was administered orally once a day for 56 days, in addition to the HFD. On the day of sacrifice, changes in the body weight, food consumption, liver weight and serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), low‑density lipoprotein (LDL), high‑density lipoprotein (HDL), triglyceride and total cholesterol (T‑CHOL) were observed, as well as changes to the liver and aorta (thoracic and abdominal) histopathology and histomorphometry. The results from the polycan groups were compared with a SIMVA 10 mg/kg oral treatment group, in addition to the sham and vehicle control groups. After the HFD‑induced hyperlipidemic hamsters were administered Polycan, there was no significant change in their body weight and food consumption when compared with the hamsters in the vehicle control group. However, the serum levels of AST, ALT, triglyceride, T‑CHOL and LDL were significantly reduced in a dose‑dependent manner when compared with the vehicle control group (P<0.05). Furthermore, the levels of liver steatosis and arteriosclerosis in the abdominal and thoracic aorta were significantly decreased in a dose‑dependent manner (P<0.01). In the SIMVA-treated group, body weight (P<0.05), the serum level of lipids (triglyceride, T‑CHOL and LDL; P<0.01) and the level of arteriosclerosis (P<0.01) were significantly reduced when compared with the vehicle control group. However, liver weight and the serum levels of AST, ALT, and liver steatosis increased when compared with the vehicle control group. Based on these results, it was concluded that polycan exerts a favorable effect in decreasing HFD‑induced hyperlipemia and associated atherosclerosis, with relatively good protective effects on liver damage.

View Figures

View References

1	Grundy SM: Cholesterol and coronary heart disease. A new era. JAMA. 256:2849–2858. 1986. View Article : Google Scholar : PubMed/NCBI
2	Neaton JD, Kuller LH, Wentworth D and Borhani NO: Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentration, and diastolic blood pressure among black and white males followed up for five years. Am Heart J. 108:759–769. 1984. View Article : Google Scholar : PubMed/NCBI
3	Tan BK, Tan CH and Pushparaj PN: Anti-diabetic activity of the semi-purified fractions of Averrhoa bilimbi in high fat diet fed-streptozotocin-induced diabetic rats. Life Sci. 76:2827–2839. 2005. View Article : Google Scholar : PubMed/NCBI
4	el-Saadany SS, el-Massry RA, Labib SM and Sitohy MZ: The biochemical role and hypocholesterolaemic potential of the legume Cassia fistula in hypercholesterolaemic rats. Nahrung. 35:807–815. 1991. View Article : Google Scholar : PubMed/NCBI
5	Sima A, Stancu C, Constantinescu E, Ologeanu L and Simionescu M: The hyperlipemic hamster - a model for testing the anti-atherogenic effect of amlodipine. J Cell Mol Med. 5:153–162. 2001. View Article : Google Scholar
6	Stary HC: The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J. 11(Supple E): 3–19. 1990. View Article : Google Scholar : PubMed/NCBI
7	Sima A, Bulla A and Simionescu N: Experimental obstructive coronary atherosclerosis in the hyperlipidemic hamster. J Submicrosc Cytol Pathol. 22:1–16. 1990.PubMed/NCBI
8	Sullivan MP, Cerda JJ, Robbins FL, Burgin CW and Beatty RJ: The gerbil, hamster, and guinea pig as rodent models for hyperlipidemia. Lab Anim Sci. 43:575–578. 1993.PubMed/NCBI
9	Bishop RW: Structure of the hamster low density lipoprotein receptor gene. J Lipid Res. 33:549–557. 1992.PubMed/NCBI
10	Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G and Duggan DE: In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos. 18:476–483. 1990.PubMed/NCBI
11	Steinmetz EF, Buckley C, Shames ML, Ennis TL, Vanvickle-Chavez SJ, Mao D, Goeddel LA, Hawkins CJ and Thompson RW: Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg. 241:92–101. 2005.
12	Czop JK: The role of beta-glucan receptors on blood and tissue leukocytes in phagocytosis and metabolic activation. Pathol Immunopathol Res. 5:286–296. 1986. View Article : Google Scholar : PubMed/NCBI
13	Estrada A, Yun CH, Van Kessel A, Li B, Hauta S and Laarveld B: Immunomodulatory activities of oat beta-glucan in vitro and in vivo. Microbiol Immunol. 41:991–998. 1997. View Article : Google Scholar : PubMed/NCBI
14	Bell S, Goldman VM, Bistrian BR, Arnold AH, Ostroff G and Forse RA: Effect of beta-glucan from oats and yeast on serum lipids. Crit Rev Food Sci Nutr. 39:189–202. 1999. View Article : Google Scholar : PubMed/NCBI
15	Lia A, Hallmans G, Sandberg AS, Sundberg B, Aman P and Andersson H: Oat beta-glucan increases bile acid excretion and a fiber-rich barley fraction increases cholesterol excretion in ileostomy subjects. Am J Clin Nutr. 62:1245–1251. 1995.PubMed/NCBI
16	Delaney B, Nicolosi RJ, Wilson TA, Carlson T, Frazer S, Zheng GH, Hess R, Ostergren K, Haworth J and Knutson N: Beta-glucan fractions from barley and oats are similarly antiatherogenic in hypercholesterolemic Syrian golden hamsters. J Nutr. 133:468–475. 2003.PubMed/NCBI
17	Wilson TA, Nicolosi RJ, Delaney B, Chadwell K, Moolchandani V, Kotyla T, Ponduru S, Zheng GH, Hess R, Knutson N, Curry L, Kolberg L, Goulson M and Ostergren K: Reduced and high molecular weight barley beta-glucans decrease plasma total and non-HDL-cholesterol in hypercholesterolemic Syrian golden hamsters. J Nutr. 134:2617–2622. 2004.PubMed/NCBI
18	Pereira FE, Motta L and Cardoso AA: Kupffer cell activation with BCG. Corynebacterium parvum or zymosan protects against acute liver injury induced by carbon tetrachloride in rats. Arq Gastroenterol. 34:157–162. 1997.PubMed/NCBI
19	Kutina SN and Zubakhin AA: Liver resistance to CCl (4)-induced injury after stimulation of macrophages with various preparations. Bull Exp Biol Med. 129:524–526. 2000. View Article : Google Scholar : PubMed/NCBI
20	Seo HP, Kim JM, Shin HD, Kim TK, Chang HJ, Park BR and Lee JW: Production of β-1,3/1,6-glucan by Aureobasidium pullulans SM-2001. Kor J Bitechnol Bioeng. 17:376–380. 2002.
21	Auger C, Caporiccio B, Landrault N, Teissedre PL, Laurent C, Cros G, Besançon P and Rouanet JM: Red wine phenolic compounds reduce plasma lipids and apolipoprotein B and prevent early aortic atherosclerosis in hypercholesterolemic golden Syrian hamsters (Mesocricetus auratus). J Nutr. 132:1207–1213. 2002.PubMed/NCBI
22	Kim HG, Une M, Kuramoto T, Noshiro M and Fujimura K: Hypocholesterolemic effect of bile acid sulfonate analogs in hamsters. Biol Pharm Bull. 24:218–220. 2001. View Article : Google Scholar : PubMed/NCBI
23	Jiang CY, Yang KM, Yang L, Miao ZX, Wang YH and Zhu HB: A 1H NMR-based metabonomic investigation of time-related metabolic trajectories of the plasma, urine and liver extracts of hyperlipidemic hamsters. PLoS One. 8:e667862013. View Article : Google Scholar :
24	Zhang X, Wu C, Wu H, Sheng L, et al: Anti-hyperlipidemic effects and potential mechanisms of action of the caffeoylquinic acid-rich Pandanus tectorius fruit extract in hamsters fed a high fat-diet. PLoS One. 8:e619222013. View Article : Google Scholar : PubMed/NCBI
25	Gao H, Long Y, Jiang X, Liu Z, Wang D, Zhao Y, Li D and Sun BL: Beneficial effects of Yerba Mate tea (Ilex paraguariensis) on hyperlipidemia in high-fat-fed hamsters. Exp Gerontol. 48:572–578. 2013. View Article : Google Scholar : PubMed/NCBI
26	Naples M, Baker C, Lino M, Iqbal J, Hussain MM and Adeli K: Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance. Am J Physiol Gastrointest Liver Physiol. 302:G1043–G1052. 2012. View Article : Google Scholar : PubMed/NCBI
27	Han LK, Zheng YN, Yoshikawa M, Okuda H and Kimura Y: Anti-obesity effects of chikusetsusaponins isolated from Panax japonicus rhizomes. BMC Complement Altern Med. 5:92005. View Article : Google Scholar : PubMed/NCBI
28	Olsson B, Bohlooly-Y M, Fitzgerald SM, Frick F, Ljungberg A, Ahrén B, Törnell J, Bergström G and Oscarsson J: Bovine growth hormone transgenic mice are resistant to diet-induced obesity but develop hyperphagia, dyslipidemia, and diabetes on a high-fat diet. Endocrinology. 146:920–930. 2005. View Article : Google Scholar
29	Yamashita J and Hayashi S: The effect of dietary protein source on plasma cholesterol level and fecal steroid excretion in obese mice. J Nutr Sci Vitaminol (Tokyo). 36:545–558. 1990. View Article : Google Scholar
30	Mukai M, Ozasa K, Hayashi K and Kawai K: Various S-GOT/S-GPT ratios in nonviral liver disorders and related physical conditions and life-style. Dig Dis Sci. 47:549–555. 2002. View Article : Google Scholar : PubMed/NCBI
31	Hoyos M, Guerrero JM, Perez-Cano R, Olivan J, Fabiani F, Garcia-Pergañeda A and Osuna C: Serum cholesterol and lipid peroxidation are decreased by melatonin in diet-induced hypercholesterolemic rats. J Pineal Res. 28:150–155. 2000. View Article : Google Scholar : PubMed/NCBI
32	Lal JJ, Sreeranjit Kumar CV, Suresh MV, Indira M and Vijayammal PL: Effect of in utero exposure of Toddy (coconut palm wine) on liver function and lipid metabolism in rat fetuses. Plant Foods Hum Nutr. 52:209–219. 1998. View Article : Google Scholar
33	Blé-Castillo JL, Rodríguez-Hernández A, Miranda-Zamora R, Juárez-Oropeza MA and Díaz-Zagoya JC: Arthrospira maxima prevents the acute fatty liver induced by the administration of simvastatin, ethanol and a hypercholesterolemic diet to mice. Life Sci. 70:2665–2673. 2002. View Article : Google Scholar : PubMed/NCBI
34	Campo GM, Squadrito F, Ceccarelli S, et al: Reduction of carbon tetrachloride-induced rat liver injury by IRFI 042, a novel dual vitamin E-like antioxidant. Free Radic Res. 34:379–393. 2001. View Article : Google Scholar : PubMed/NCBI
35	Mansuy D, Sassi A, Dansette PM and Plat M: A new potent inhibitor of lipid peroxidation in vitro and in vivo, the hepatoprotective drug anisyldithiolthione. Biochem Biophys Res Commun. 135:1015–1021. 1986. View Article : Google Scholar : PubMed/NCBI
36	Taylor SL and Tappel AL: Effect of dietary antioxidants and phenobarbital pretreatment on microsomal lipid peroxidation and activation by carbon tetrachloride. Life Sci. 19:1151–1160. 1976. View Article : Google Scholar : PubMed/NCBI
37	Krizková L, Duracková Z, Sandula J, Slamenová D, Sasinková V, Sivonová M and Krajcovic J: Fungal beta-(1–3)-D-glucan derivatives exhibit high antioxidative and antimutagenic activity in vitro. Anticancer Res. 23:2751–2756. 2003.
38	Sener G, Toklu H, Ercan F and Erkanli G: Protective effect of beta-glucan against oxidative organ injury in a rat model of sepsis. Int Immunopharmacol. 5:1387–1396. 2005. View Article : Google Scholar : PubMed/NCBI
39	Forrester JS, Makkar R and Shah PK: Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation. 111:1847–1854. 2005. View Article : Google Scholar : PubMed/NCBI
40	Kamada T, Hata J, Kusunoki H, Ito M, Tanaka S, Kawamura Y, Chayama K and Haruma K: Eradication of Helicobacter pylori increases the incidence of hyperlipidaemia and obesity in peptic ulcer patients. Dig Liver Dis. 37:39–43. 2005. View Article : Google Scholar : PubMed/NCBI
41	Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI and Elisaf MS: Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 148:635–640. 2004. View Article : Google Scholar : PubMed/NCBI
42	Cheng JW: Rosuvastatin in the management of hyperlipidemia. Clin Ther. 26:1368–1387. 2004. View Article : Google Scholar : PubMed/NCBI
43	Pirat B, Korkmaz ME, Eroǧlu S, Tayfun E, Yildirir A, Uluçam M, Ozin B and Müderrisoǧlu H: The effects of simvastatin combined with different antioxidant vitamin regimens on serum lipid profile in patients with low HDL cholesterol levels. Anadolu Kardiyol Derg. 4:318–322. 2004.(In Turkish). PubMed/NCBI
44	Zdrenghea D, Gligor E, Ossian V and Pop D: The effect of simvastatin associated with ranitidine and alcohol upon serum lipids. Rom J Intern Med. 42:143–148. 2004.PubMed/NCBI
45	Morishita S, Saito T, Mishima Y, Mizutani A, Hirai Y, Koyama S and Kawakami M: Strains and species differences in experimental hyperlipidemia. Nihon Yakurigaku Zasshi. 87:259–264. 1986.(In Japanese). View Article : Google Scholar : PubMed/NCBI
46	Ausman LM, Rong N and Nicolosi RJ: Hypocholesterolemic effect of physically refined rice bran oil: studies of cholesterol metabolism and early atherosclerosis in hypercholesterolemic hamsters. J Nutr Biochem. 16:521–529. 2005. View Article : Google Scholar : PubMed/NCBI
47	Deepa PR and Varalakshmi P: Atheroprotective effect of exogenous heparin-derivative treatment on the aortic disturbances and lipoprotein oxidation in hypercholesterolemic diet fed rats. Clin Chim Acta. 355:119–130. 2005. View Article : Google Scholar : PubMed/NCBI
48	Illman RJ and Topping DL: Effects of dietary oat bran on faecal steroid excretion, plasma volatile fatty acids and lipid synthesis in the rat. Nutr Res. 5:839–846. 1985. View Article : Google Scholar
49	Judd PA and Truswell AS: The effects of rolled oats on blood lipids and fecal steroid excretion in man. Am J Clin Nutr. 34:2061–2067. 1981.PubMed/NCBI
50	Rieckhoff D, Trautwein EA, Mälkki Y and Ebersdobler HF: Effects of different cereal fibers on cholesterol and bile acid metabolism in the Syrian golden hamster. Cereal Chem. 76:788–795. 1999. View Article : Google Scholar
51	Anderson JW, Story L, Sieling B, Chen WJ, Petro MS and Story J: Hypocholesterolemic effects of oat-bran or bean intake for hypercholesterolemic men. Am J Clin Nutr. 40:1146–1155. 1984.PubMed/NCBI
52	Kirby RW, Anderson JW, Sieling B, Rees ED, Chen WJ, Miller RE and Kay RM: Oat-bran intake selectively lowers serum low-density lipoprotein cholesterol concentrations in hypercholesterolemic men. Am J Clin Nutr. 34:824–829. 1981.PubMed/NCBI